Announced Thu, 17 Sept, 2026 · 17:03 IST
IOLCP plans INR500 cr capex for Ibuprofen, CDMO and specialty chemicals
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsMgmt Evaded Key QuestionInvestor Communications View source PDFExplain this filing
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹197.49
prior close
₹198.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.1+1.5+1.2+0.9+2.4+1.8+5.1+2.3+3.1+2.2————
Up moveDown movePending
AI summary
IOLCP to invest INR500 cr across 3 projects: 6,000 MTPA Ibuprofen capacity expansion to 18,000 MTPA by Dec 2027; new CDMO facility (1,500 mn tablets per year, EU GMP certified, Q3 FY27 launch); specialty chemical tolling plant. Funded via internal accruals (30% already spent). Targets 25-30% top line addition by FY29 and 15% ROCE at full ramp-up. Management highlighted backward integration and stable Ibu prices as margin tailwind.
Likely market impact
Funded via internal accruals, targets 25-30% revenue growth by FY29 with margin lift from integrated Ibu. Positive for stock.